TEM - Public offerings

Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter and year ended December 31, 2025. Fourth quarter revenue of $367.2 million, up 83.0% year-over-year with 33.5% organic growth (excluding Ambry) Diagnostics revenue of $266.9 million in the fourth quarter, representing 121.6% growth year-over-year, driven by Oncology volume growth of 29% and Hereditary volume growth of 23% MRD volume was ~4,700 tests in the fourth quarter, up 56% quarter-over-quarter Data and Applications revenue of $100.4 million in the fourth quarter, representing 25.1% year-over-year g

Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended September 30, 2025. Revenue grew 84.7% year-over-year to $334.2 million in the third quarter of 2025 Gross profit reached $209.9 million in the third quarter of 2025, an improvement of 98.4% year-over-year 217,000 clinical tests delivered in the quarter, representing 33% year-over-year volume growth, with Oncology volume growth accelerating to 27% and Hereditary at 37% Insights bookings of $150 million across multiple new contracts with year-over-year revenue growth of 37.6% in the quarter Increasing fu

Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended June 30, 2025. Revenue increased 89.6% year-over-year to $314.6 million in the second quarter Genomics revenue increased 115.3% year-over-year to $241.8 million on accelerating year-over-year volume growth in Oncology (26%) and Hereditary (32%) testing Data and services revenue increased 35.7% year-over-year to $72.8 million, led by Insights (data licensing), which grew 40.7% year-over-year Quarterly gross profit was $195.0 million, a 158.3% year-over-year increase Issued $750 million of 0.75% conv

Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter and year ended December 31, 2024. Year-over-year revenue growth accelerated to 35.8% in the fourth quarter of 2024 Gross profit growth accelerated to 49.7% in the fourth quarter of 2024, led by Data and services Ended the year with $940 million in Total Remaining Contract Value and 140% net revenue retention Closed the acquisition of Ambry Genetics on February 3, 2025 Increases revenue guidance to $1.24 billion for 2024 and expect full year 2025 Adjusted EBITDA of approximately $5 million, an improvement

Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced select, preliminary, unaudited results for the fourth quarter and full year ended December 31, 2024. Full Year 2024 Select, Preliminary, Unaudited Financial Results Revenue of approximately $693 million, representing approximately 30% growth year-over-year Continued improvement in adjusted EBITDA compared to the prior year Fourth Quarter 2024 Select, Preliminary, Unaudited Financial Results Revenue of approximately $200 million, an increase of approximately 35% year-over-year Continued trend of sequential improvement in adjusted EBITD

Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter that ended September 30, 2024. The company also announced that it has entered into an agreement to acquire Ambry Genetics, a leader in genetic testing that aims to improve health by understanding the relationship between genetics and disease. Revenue increased 33.0% year-over-year to $180.9 million in the third quarter of 2024 Data and services revenue growth accelerated to 64.4% year-over-year Genomics unit growth accelerated to 23.9% annually with rising average revenue per clinical test Net Loss of $(75.8 mi

Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter that ended June 30, 2024, and provided recent business highlights. Revenue increased 25% year-over-year to $166.0 million in the second quarter of 2024 Data licensing revenue growth accelerated to 40% year-over-year Expanded into the minimal residual disease (MRD) market with the launch of both tumor-naïve and tumor-informed assays Established a joint venture with Softbank to enter the Japanese market Raised $410.7 million of gross proceeds in initial public offering Net Loss of ($552.2 million), larg